Clinical Trial Update: PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating PFO closure versus oral anticoagulants or antiplatelet therapy to prevent recurrent stroke in adults aged 60 to 80 with c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryptogenic Ischemic Stroke
• Patent Foramen Ovale

Drugs mentioned

• Antiplatelet therapy (antiplatelet agents)
• Oral anticoagulants
• PFO closure device

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Cryptogenic Ischemic Stroke, Patent Foramen Ovale | Phase 3 | Status: RECRUITING